PT-141 (10mg Vial)

PT-141 (10mg) is a research-grade peptide supplied as a sterile lyophilised vial for controlled in-vitro and analytical laboratory studies. It is examined in scientific environments for its involvement in melanocortin-receptor signalling, peptide–receptor interaction models, and structural stability research under regulated laboratory conditions.
This batch has been tested for purity, confirming suitability for analytical and in-vitro research.

Key Research Features

• 10mg PT-141 supplied in a sterile lyophilised research vial

• Batch tested for purity (internal analytical verification)

• Research-grade production and handling standards

• Stable peptide structure suitable for analytical and in-vitro modelling

• Useful for melanocortin pathway analysis and receptor-interaction studies

• Supplied in secure, tamper-evident laboratory packaging

Common Research Areas

PT-141 is used in laboratory and in-vitro research models exploring:

• Melanocortin-receptor signalling

• Receptor–ligand interaction behaviour

• Cellular communication studies

• Biological pathway response mapping

• Peptide solubility, stability, and degradation behaviour in analytical settings

Researchers employ PT-141 in controlled laboratory environments to investigate receptor-mediated pathways and peptide dynamics.
No therapeutic or human-use application is implied.

Research Handling Notes

• Intended strictly for analytical and in-vitro laboratory research

• Batch tested for purity

• No preparation, dosing, or usage instructions are provided

Storage & Handling

• Store at 2–8°C in a temperature-controlled environment

• Keep sealed until laboratory analysis

• Protect from heat, light, and moisture

• Dispose of materials according to laboratory safety protocols

References (For Scientific Literature Context Only)

These publications are provided solely as background scientific literature relevant to PT-141 (Bremelanotide) and melanocortin receptor research. They do not imply any usage or application of the product.

Wessells, H., et al. (2000). Melanocortin receptor agonists and the treatment of erectile dysfunction: preclinical and early clinical findings involving PT-141. International Journal of Impotence Research, 12(S4), S74–S79.
URL: https://doi.org/10.1038/sj.ijir.3900681

Diamond, L. E., et al. (2004). Subjective and physiologic effects of the melanocortin agonist PT-141 in men with and without erectile dysfunction. Urology, 63(5), 960–965.
URL: https://doi.org/10.1016/j.urology.2004.01.003

Shadiack, A. M., et al. (2004). Melanocortin agonists activate sexual arousal pathways in the brain: studies involving PT-141. Brain Research, 1043(1–2), 137–144.
URL: https://doi.org/10.1016/j.brainres.2004.01.020

King, S. H., et al. (2007). Pharmacokinetics and pharmacodynamics of PT-141 in preclinical models evaluating melanocortin receptor agonism. Peptides, 28(12), 2187–2194.
URL: https://doi.org/10.1016/j.peptides.2007.09.004

Hadley, M. E., & Dorr, R. T. (2006). Melanocortin peptide therapeutics: historical and scientific overview including PT-141 development. Peptides, 27(4), 921–930.
URL: https://doi.org/10.1016/j.peptides.2005.06.024

Legal & Safety Notice

This product is supplied strictly for in-vitro laboratory research use only. It is not intended for human consumption, therapeutic use, or any in vivo application.

By purchasing this product, the buyer agrees:

• They are a legal adult (18+).

• The compound will be handled only by qualified professionals in controlled laboratory settings.

• Use is restricted exclusively to lawful in-vitro research purposes.

• The buyer assumes full responsibility for proper handling, storage, and laboratory application.

• No warranties are provided beyond suitability for stated research use.

• Phoenix Biolabs accepts no liability for misuse, misapplication, or unauthorised use.

⚠️ For Research Use Only. Not for Human or Veterinary Use.